Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SI | P14410 | 2/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228861 | 1.00 | HSD11B1 (0.41) | HSD11B1MAOAMAOBXDHEGFR | |
| SCHEMBL4227589 | 0.91 | CYP1A2 (0.37) | MAOBEGFRACHEMGAMGAA | |
| SCHEMBL4227584 | 0.91 | CYP1A2 (0.37) | MAOBEGFRACHEMGAMGAA | |
| SCHEMBL4233709 | 0.89 | NFE2L2 (0.42) | MAOAMAOBCARM1ACHEMGAM | |
| SCHEMBL4233711 | 0.89 | NFE2L2 (0.42) | MAOAMAOBCARM1ACHEMGAM | |
| SCHEMBL4235725 | 0.84 | HSD11B1 (0.38) | HSD11B1EGFRACHEMGAMGAA | |
| SCHEMBL4235727 | 0.84 | HSD11B1 (0.38) | HSD11B1EGFRACHEMGAMGAA | |
| SCHEMBL4237652 | 0.84 | CYP19A1 (0.38) | ACHEALDH1A1 | |
| SCHEMBL4237655 | 0.84 | CYP19A1 (0.38) | ACHEALDH1A1 | |
| SCHEMBL4237636 | 0.82 | ESR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | claimed |
| EP-1841723-A1 | DECALINE DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | Universität Dortmund (DE) | 2007-10-10 | — | — | EP | claimed |
| WO-2006069787-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | Universität Dortmund (DE) | 2006-07-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | CHAT, DLAT, CPT1A | HSD11B1 43/4885MAOA 1501/4885MAOB 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.